The effect of oral channa striatus extract on post lower segment caesarian section (LSCS) women

The effect of oral channa striatus extract on post lower segment caesarian section (LSCS) women: a randomized, double-blind, placebo-controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11960786

Enrollment

Registered

2015-01-21

Start date

2011-03-15

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To assess the effect of oral channa striatus extract on post lower segment caesarian women in terms of post operative pain, wound healing, safety profile and uterine involution. Pregnancy and Childbirth

Interventions

The patients were randomized to two groups in the ratio of 1:1 using computer develop generation numbers in the block of four. The treatment group was prescribed 500 mg (2 capsules) per day of freeze

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 40 years 2. No present active medical, surgical and gynecological problems 3. First LSCS (elective or emergency)

Exclusion criteria

Exclusion criteria: 1. Taking any form of herbal extract in the last 3 months before study entry and during the study period 2. History of drug or alcohol abuse. 3. Taking fresh channa striatus during study period 4. Patient taking warfarin or heparin 5. Clinical relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, haematologic, connective tissue disease or other major systemic diseases that would influence the interpretation of results 6. Patients with medical disorder requiring steroid or immunosuppressive therapy 7. Patient with chronic cough or other condition which may cause a rise in intra-abdominal pressure 8. Presence of any congenital anterior abdominal wall defects 9. Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study. 10. Evidence of uncooperative attitude, including poor compliance including inability to attend follow-up visit

Design outcomes

Primary

Measure	Time frame
1. Post-operative pain score 2. Wound healing based on: 2.1. Wound Evaluation Scale (WES) 2.2. Visual Analogue Scale (VAS) 2.3. Patient’s satisfaction score (PSS) 3. Safety profile based on Renal Function Test (RFT), Liver Function Test (LFT) and Full Blood Count (FBC) 4. Mean anteroposterior measurement of the uterus in longitudinal and oblique transverse planes 5. Mean resistive index (RI) and pulsatility index (PI) of the uterine artery 6. Mean resistive index (RI) and pulsatility index (PI) and of the artery of the superficial skin wound Measured at baseline (day 3), two weeks, four weeks and six weeks post-operatively.	—

Measure

Time frame

1. Post-operative pain score 2. Wound healing based on: 2.1. Wound Evaluation Scale (WES) 2.2. Visual Analogue Scale (VAS) 2.3. Patient’s satisfaction score (PSS) 3. Safety profile based on Renal Function Test (RFT), Liver Function Test (LFT) and Full Blood Count (FBC) 4. Mean anteroposterior measurement of the uterus in longitudinal and oblique transverse planes 5. Mean resistive index (RI) and pulsatility index (PI) of the uterine artery 6. Mean resistive index (RI) and pulsatility index (PI) and of the artery of the superficial skin wound Measured at baseline (day 3), two weeks, four weeks and six weeks post-operatively.

—

Countries

Malaysia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026